苏州沪云

Suzhou Huyun Biological Technology is a clinical-stage biopharmaceutical company based in the Suzhou Industrial Park, China, specializing in the development of innovative therapies for cardiovascular and metabolic diseases. The company's primary focus is on high-barrier biological drugs, particularly recombinant proteins. Its lead candidate, HY-001, is a recombinant human brain natriuretic peptide (rhBNP) currently in Phase 3 clinical trials for the treatment of acute heart failure. Suzhou Huyun leverages its expertise in protein engineering to develop a pipeline of therapies targeting high-prevalence conditions such as heart failure and myocardial infarction. The company aims to address significant unmet medical needs in the cardiovascular space through its specialized R&D platform and pipeline of next-generation natriuretic peptide therapies. Suzhou Huyun has received backing from prominent regional investors and is a recognized member of the Suzhou Biobay biotechnology cluster.